24036-63-3

Usage

Uses

Used in Organic Synthesis:
1-Phenyl-1H-[1,2,4]triazole-3-carboxylic acid is used as a building block in organic synthesis for its structural flexibility and the ability to form a wide range of chemical compounds.
Used in the Production of Organic Light-Emitting Diodes (OLEDs):
1-Phenyl-1H-[1,2,4]triazole-3-carboxylic acid is utilized as a key component in the manufacturing of OLEDs, contributing to their light-emitting properties and overall performance.

InChI:InChI=1/C9H7N3O2/c13-9(14)8-10-6-12(11-8)7-4-2-1-3-5-7/h1-6H,(H,13,14)

Upstream product

• 28663-68-5 ethyl (phenylhydrazono)chloroacetate 
• 1019-95-0 ethyl 1-phenyl-1H-1,2,4-triazole-3-carboxylate 
• 62-53-3 aniline 
• 57226-96-7 methyl 1-phenyl-1H-1,2,4-triazole-3-carboxylate 
• 4928-88-5 methyl 1H-1,2,4-triazole-3-carboxylate 
• 98-80-6 phenylboronic acid 
• 2999-46-4 Ethyl isocyanoacetate 
• 61698-27-9 3-acetyl-1-phenyl-1,2,4-triazole 

Downstream Products

• 2518-43-6 (1-phenyl-1H-1,2,4-triazol-3-yl)methanol 
• 1613021-84-3 (S)-N-(1-([1,2,4]triazolo[4,3-a]pyrazin-8-yl)pyrrolidin-3-yl)-1-phenyl-1H-1,2,4-triazole-3-carboxamide 
• 1613021-48-9 N-[(3S)-3-(hydroxymethyl)-1-imidazo[1,2-a]pyrazin-8-yl-pyrrolidin-3-yl]-1-phenyl-1,2,4-triazole-3-carboxamide 
• 1613021-45-6 N-[(3S)-3-(hydroxymethyl)-1-pyrrolo[1,2-a]pyrazin-1-yl-pyrrolidin-3-yl]-1-phenyl-1,2,4-triazole-3-carboxamide 
• 1613022-30-2 1-phenyl-1H-[1,2,4]triazole-3-carboxylic acid [1-(3-methylpyrrolo[1,2-a]pyrazin-1-yl)-pyrrolidin-3-yl]amide 
• 1613021-92-3 (S)-N-(1-(imidazo[1,2-a]pyrazin-8-yl)pyrrolidin-3-yl)-1-phenyl-1H-1,2,4-triazole-3-carboxamide 
• 1613021-27-4 C₂₃H₂₅N₇O 
• 1613021-20-7 C₂₂H₂₃N₇O 
• 1613021-98-9 (S)-1-phenyl-N-(1-(pyrrolo[1,2-a]pyrazin-1-yl)pyrrolidin-3-yl)-1H-1,2,4-triazole-3-carboxamide 
• 1613021-67-2 (S)-1-phenyl-N-(1-(pyrazolo[1,5-a]pyrazin-4-yl)pyrrolidin-3-yl)-1H-1,2,4-triazole-3-carboxamide 
• 1443759-20-3 (2,2-dimethyl-piperazin-1-yl)-(1-phenyl-1-H-[1,2,4]-triazol-3-yl)-methanone trifluoroacetate 
• 1443757-54-7 [4-(2-cyclopentylmethyl-3-methyl-3H-benzoimidazole-5-carbonyl)-2,2-dimethyl-piperazin-1-yl]-(1-phenyl-1H-[1,2,4]-triazol-3-yl)-methanone 
• 1443756-74-8 [4-(3-isopropyl-benzoyl)-2,2-dimethyl-piperazin-1-yl]-(1-phenyl-1H-[1,2,4]triazol-3-yl)-methanone 
• 1443759-75-8 [4-(4-amino-3-methylamino-benzoyl)-2,2-dimethyl-piperazin-1-yl]-(1-phenyl-1H-[1,2,4]triazol-3-yl)-methanone 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of glycolamide, glycinamide, and β-amino carbonyl 1,2,4-triazole derivatives as DPP-4 inhibitors

Through modification of the skeleton of Sitagliptin and Vildagliptin, we successfully synthesized and built-up four series of 1,2,4-triazole derivatives, containing N,O-disubstituted glycolamide, N,N′-disubstituted glycinamide, β-amino ester, and β-amino

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.

PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.

Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly

A major challenge in drug discovery is to develop and improve methods for targeting protein-protein interactions. Further exemplification of the REPLACE (REplacement with Partial Ligand Alternatives through Computational Enrichment) strategy for generatin